Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 11/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 11/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.46 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.46 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.46 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SPR | P35270 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495294 | 0.90 | NFE2L2 (0.67) | KEAP1NFE2L2NSD2NSD1NSD3 | |
| SCHEMBL3494173 | 0.88 | KEAP1 (0.52) | KEAP1NFE2L2MEN1KMT2ATP53 | |
| SCHEMBL18733521 | 0.88 | NFE2L2 (0.57) | KEAP1NFE2L2SPR | |
| SCHEMBL3494108 | 0.87 | KEAP1 (0.64) | KEAP1NFE2L2KMT2AMAPTTP53 | |
| SCHEMBL3493401 | 0.83 | KEAP1 (0.48) | KEAP1NFE2L2MEN1KMT2AMAPT | |
| SCHEMBL18707107 | 0.82 | NFE2L2 (0.53) | KEAP1NFE2L2TP53POLBSPR | |
| SCHEMBL13848786 | 0.81 | KEAP1 (0.72) | KEAP1NFE2L2KMT2AMAPTTP53 | |
| SCHEMBL18700800 | 0.79 | NFE2L2 (0.52) | KEAP1NFE2L2MEN1KMT2AMAPT | |
| SCHEMBL18700882 | 0.78 | NFE2L2 (0.68) | KEAP1NFE2L2MAPTTP53SPR | |
| SCHEMBL18700747 | 0.78 | NFE2L2 (0.68) | KEAP1NFE2L2MAPTTP53SPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-1984355-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | Takeda Pharmaceutical Company Limited (JP) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007094513-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | KEAP1 488/4885NFE2L2 1103/4885MEN1 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.